OUTREACH AGENDA

CD4淋巴细胞的进行性丧失与慢性粒细胞白血病的进展相关 艾滋病病毒感染到艾滋病。目前，疾病进展的其他相关因素 都是缺乏的。因此，艾滋病毒感染者的常规免疫表型 是合理的。不幸的是，对其他淋巴细胞标记物的分析还没有 已经做了足够的工作，以确定它们是否也可以预测 疾病的病程。免疫系统是许多因素相互作用的复杂系统 单元类型。CD4淋巴细胞室的进行性下降 可能导致其他淋巴细胞亚群比例的变化。这个 问题是，其他淋巴细胞表面抗原的变化 与疾病进展相关，更理想的是，稳定或恢复 对有效药物治疗的反应。为了调查这一问题， 单色免疫荧光技术不得不开发出双色 能力。随着双色免疫荧光的使用，一些激活 淋巴细胞亚群上的分化标记物显示 良好的状态与疾病的进展密切相关。然而，这些标记是 没有在评估药物的临床试验的背景下进行调查 有效性。一个主要原因是分析 广泛的面板双色配置管。最近又出现了第三种荧光色素 对于常规的三色免疫荧光已经商业化。 拟议中的研究希望利用这项最新技术来巩固 将多个双色剖面管放入更有限的三色面板中 异形管。这将允许更易于管理的临床评估 标本。此外，3种不同抗体的组合可以精确定位 一种特殊的淋巴细胞亚群现在可以常规地 调查过了。这项研究的目标之一将是验证和 证明从常规双色分析切换到三色分析是正确的。这将是 对登记的个人的淋巴细胞进行更积极的分析 在ACTG临床试验中，使用扩展的三色分析管面板。 希望在该项目的随后几年，常规三色 免疫表型将识别和验证淋巴细胞亚群的变化 与艾滋病毒疾病进展和/或药物疗效相关的标志物。

The progressive loss of CD4 lymphocytes correlates with the progression of HIV infection to AIDS. At present, other correlates of disease progression are lacking. Thus, routine immunophenotyping of HIV-infected individuals is justified. Unfortunately, analysis of other lymphocyte markers has not been sufficiently done to determine if they also can predict changes in the course of the disease. The immune system is a complex interaction of many cell types. A progressive decline in the CD4 lymphocyte compartment is likely to cause shifts in the proportions of other lymphocyte subsets. The question arises as to whether changes in other lymphocyte surface antigens correlate with disease progression and more ideally, stabilize or revert in response to efficacious drug therapy. In order to investigate this issue, single color immunofluorescence technology had to develop a dual color capability. With the use of 2-color immunofluorescence, some activation and differentiation markers on lymphocyte subset cells showed promise of being good correlates of disease progression. However, these markers were not investigated in the context of clinical trials to assess drug effectiveness. A major reason was the cost and time required to analyze an extensive panel of 2-color profile tubes. Recently a third fluorochrome for routine 3-color immunofluorescence has become commercially available. The proposed study hopes to utilize this newest technology to consolidate a number of 2-color profile tubes into a more limited panel of 3-color profile tubes. This would allow a more manageable evaluation of clinical specimens. In addition, combinations of 3 discrete antibodies to pinpoint a particular subpopulation of lymphocytes can now be routinely investigated. One of the goals of this research will be to validate and justify the switch from routine 2-color to 3-color analysis. This will enable a more aggressive analysis of lymphocytes from individuals enrolled in ACTG clinical trials using an expanded panel of 3-color analysis tubes. It is hoped that in the subsequent years of this project, routine 3-color immunophenotyping will identify and validate changes in lymphocyte subset markers that correlate with HIV disease progression and/or drug efficacy.